Angela Karsten, APRN
Nurse Practitioner · Omaha, NENPI 1851652028
Payments from drug & device makers
Across 192 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$452
- 180 Medical, Inc.$381
- Astellas Pharma US Inc$329
- Johnson & Johnson$324
- Teleflex LLC$246
- Urogen Pharma, Inc.$223
- plus $3K from 32 others
What the payments were for
- Food & beverage$4,17993%
- Education$2947%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $452 |
| 180 Medical, Inc. | 16 | $381 |
| Astellas Pharma US Inc | 9 | $329 |
| Johnson & Johnson | 16 | $324 |
| Teleflex LLC | 4 | $246 |
| Urogen Pharma, Inc. | 7 | $223 |
| Merck | 13 | $210 |
| Dendreon Pharmaceuticals LLC | 9 | $203 |
| Boston Scientific | 6 | $190 |
| Bayer | 6 | $181 |
| Sumitomo Pharma America, Inc. | 9 | $161 |
| Calyxo, Inc. | 1 | $146 |
| Tolmar Pharmaceuticals, Inc. | 7 | $143 |
| Endo Pharmaceuticals Inc. | 8 | $121 |
| Janssen Scientific Affairs, LLC | 1 | $118 |
| Tolmar, Inc. | 5 | $100 |
| Accord Healthcare, Inc. | 3 | $86 |
| Procept Biorobotics Corporation | 3 | $73 |
| Pfizer | 4 | $68 |
| Coloplast | 3 | $65 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $64 |
| Urovant Sciences Inc | 4 | $62 |
| Verity Pharmaceuticals Inc. | 3 | $53 |
| Myovant Sciences Inc. | 3 | $51 |
| Ferring Pharmaceuticals Inc. | 1 | $49 |
| Photocure Inc | 2 | $49 |
| BD | 2 | $45 |
| Endo USA, Inc. | 2 | $42 |
| KARL Storz Endoscopy-america | 1 | $40 |
| Rochester Medical Corporation | 2 | $39 |
| Blue Earth Diagnostics | 2 | $32 |
| Palette Life Sciences, Inc. | 2 | $28 |
| Smith+Nephew | 1 | $26 |
| Antares Pharma, Inc. | 1 | $21 |
| Immunitybio, Inc. | 1 | $21 |
| Novartis | 1 | $18 |
| Progenics Pharmaceuticals, Inc. | 1 | $16 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$171
- CVAC Aspiration System$146
- Erleada$118
- Balversa$118
- Pipeline$118
How this compares
$4,473 in reported general payments places this provider in the 90th percentile of 924 nurse practitioner providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 87 | $58,295 |
| GemtesaVibegron | 27 | $30,883 |
| PremarinEstrogens, Conjugated | 28 | $12,414 |
| Tamsulosin Hcl | 729 | $9,459 |
| Desmopressin AcetateDesmopressin (Nonrefrigerated) | 24 | $4,983 |
| Finasteride | 452 | $4,416 |
| Testosterone | 30 | $4,322 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 54 | $2,317 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 27 | $2,194 |
| Tolterodine Tartrate ErTolterodine Tartrate | 19 | $1,748 |
| Estradiol | 24 | $1,615 |
| Solifenacin Succinate | 49 | $1,582 |
| Methenamine Hippurate | 19 | $1,550 |
| Oxybutynin Chloride ErOxybutynin Chloride | 131 | $1,483 |
| Testosterone Cypionate | 27 | $1,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $329 | $58,29587 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $161 | $30,88327 claims |
| PfizerPremarin | $68 | $12,41428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 924 nurse practitioner providers in Nebraska.
Other nurse practitioner in Omaha
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
- Kathleen HealeyOmaha$36K
- Katie RuchOmaha$26K
- Amanda GuggenmosOmaha$23K
- Amy YagerOmaha$15K
- Cara SchiesslerOmaha$14K
- Lindsay OneilOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.